Comparison of disease activity measures for antineutrophil cytoplasmic autoantibody (ANCA)- Associated vasculitis

Annals of the Rheumatic Diseases

Volumn 68, Issue 1, 2009, Pages 103-106

  Merkel, P A ^a,b   Cuthbertson, D D ^a,c   Hellmich, B ^a,d   Hoffman, G S ^a,e   Jayne, D R W ^a,f   Kallenberg, C G M ^a,g   Krischer, J P ^a,c   Luqmani, R ^a,h   Mahr, A D ^a,i   Matteson, E L ^a,j   Specks, U ^a,j   Stone, J H ^a,k  

^a Vasculitis Clinical Research Consortium

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d Kreiskrankenhaus Plochingen   (Germany)

^e LERNER RESEARCH INSTITUTE   (United States)

^f ADDENBROOKE S HOSPITAL   (United Kingdom)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ Hospital Cochin ^*  (France)

^j MAYO CLINIC   (United States)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NEUTROPHIL CYTOPLASMIC ANTIBODY;

ANCA ASSOCIATED VASCULITIS; ARTICLE; BIRMINGHAM VASCULITIS ACTIVITY SCORE; CORRELATION COEFFICIENT; DISEASE ACTIVITY; EXERCISE; HUMAN; INSTRUMENT; MEDICAL SPECIALIST; MICROSCOPIC POLYANGIITIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PATIENT ASSESSMENT; PRIORITY JOURNAL; RELIABILITY; SCORING SYSTEM; TEST RETEST RELIABILITY; WEGENER GRANULOMATOSIS;

ACUTE DISEASE; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; AUTOANTIBODIES; EUROPE; HUMANS; LINEAR MODELS; OBSERVER VARIATION; RANDOM ALLOCATION; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; UNITED STATES; VASCULITIS;

EID: 58349117224     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.097758     Document Type: Article

References (12)

1. Hoffman GS, Gross WL. Wegener's granulomatosis: clinical aspects. In: Hoffman GS, Weyand CM, eds. Inflammatory diseases of blood vessels. New York: Marcel Dekker, 2001:381-97.
2. Bacon PA, Adu D. Microscopic polyangiitis: clinical aspects. In: Hoffman GS, Weyand CM, eds. Inflammatory diseases of blood vessels. New York: Marcel Dekker, 2001:355-363.
3. Seo P, Min N, Holbrook JT, Hoffman GS, Merkel PA, Spiera R, et al. Damage from Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum 2005; 52:2168-78.
4. Merkel PA, Seo P, Aries P, Neogi T, Villa-Forte A, Boers M, et al. Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. J Rheumatol 2005; 32:2488-95.
5. Luqmani RA, Bacon PA, Moots RJ, Janssen BA. Pall A, Emery P, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. OJM 1994; 87:671-8.
6. Stone JH, Hoffman GS, Merkel PA, Min Yl, Uhlfelder ML, Hellmann DB, et al. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. Arthritis Rheum 2001; 44:912-20.
7. Jayne D, Rasmussen N, Andrassy K, Bacon P, Cohen Tervaert JW, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:36-44.
8. Guillevin L, Cohen P, Mahr A, Arene JP, Mouthon L, Puechal X, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 2003; 49:93-100.
9. Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer L, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997; 40):2187-98.
10. WGET Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352:351-61.
11. de Groot K, Gross WL, Herlyn K, Reinhold-Keller E. Development and validation of a disease extent index for Wegener's granulomatosis. Clin Nephrol 2001; 55:31-8.
12. Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary 0, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine /Baltimore) 1996; 75:17-28.